Conclusions

The amyloidoses are a diverse group of disorders characterized by pathologic protein folding, conformation, and deposition.12 These disorders exhibit considerable clinical heterogeneity but share many pathogenic mechanisms. Current therapies are directed mostly toward reducing the supply of precursor proteins. Improved understanding of the pathogenic mechanisms is likely to yield novel approaches to therapy of these diseases.

17. Buxbaum JN, Tagoe CE: The genetics of amyloidoses. Ann Rev Med 51:543-569, 2000.

18. Yan SD, Zhu H, Zhu A, et al.: Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat Med 6:643-651, 2000.

19. Jacobson DR, Pastore RD, Yaghoubian R, et al.: Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med 336:466-473, 1997.

20. Walsh DM, Klyubin I, Fadeeva JV, et al.: Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416:535-539, 2002.

21. Skinner M, Sanchorawala V, Seldin DC, et al.: High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 140:85-93, 2004.

22. Crocitto LE, Eastham JA, Zien L, Skinner EC, Huffman JL: Management and evaluation of localized amyloidosis of the bladder: two case reports. Urology 44:282-284, 1994.

23. O'Regan A, Fenlon HM, Beamis JF Jr, Steele MP, Skinner M, Berk JL: Tracheobronchial amyloidosis. The Boston University experience from 1984 to 1999. Medicine (Baltimore) 79:69-79, 2000.

24. Gertz MA, Lacy MQ, Dispenzieri A: Amyloidosis. Hematol Oncol Clin North Am 13:1211-1233, ix, 1999.

25. Gertz MA, Lacy MQ, Dispenzieri A: Amyloidosis: recognition, confirmation, prognosis, and therapy. Mayo Clin Proc 74:490-494, 1999.

26. Dubrey SW, Cha K, Skinner M, LaValley M, Falk RH: Familial and primary (AL) cardiac amyloidosis: echocar-diographically similar diseases with distinctly different clinical outcomes. Heart 78:74-82, 1997.

27. Dispenzieri A, Kyle RA, Gertz MA, et al.: Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet 361:1787-1789, 2003.

28. Palladini G, Campana C, Klersy C, et al.: Serum N-termi-nal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 107:2440-2445, 2003.

29. Gertz MA, Lacy MQ, Dispenzieri A: Immunoglobulin light chain amyloidosis and the kidney. Kidney Int 61:1-9, 2002.

30. Rajkumar SV, Gertz MA, Kyle RA: Prognosis of patients with primary systemic amyloidosis who present with dominant neuropathy. Am J Med 104:232-237, 1998.

31. Perfetti V, Garini P, Vignarelli MC, Marinone MG, Zorzoli I, Merlini G: Diagnostic approach to and follow-up of difficult cases of AL amyloidosis. Haematologica 80:409-415, 1995.

32. Grateau G: The relationship between familial Mediterranean fever and amyloidosis. Curr Opin Rheumatol 12:61-64, 2000.

33. Bergethon PR, Sabin TD, Lewis D, Simms RW, Cohen AS, Skinner M: Improvement in the polyneuropathy associated with familial amyloid polyneuropathy after liver transplantation. Neurology 47:944-951, 1996.

34. Kyle RA, Rajkumar SV: Monoclonal gammopathies of undetermined significance. Hematol Oncol Clin North Am 13:1181-1202, 1999.

35. Hawkins PN, Aprile C, Capri G, et al.: Scintigraphic imaging and turnover studies with iodine-131 labelled serum amyloid P component in systemic amyloidosis. Eur JNucl Med 25:701-708, 1998.

36. Pardanani A, Witzig TE, Schroeder G, et al.: Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis. Blood 101:827-830, 2003.

37. Dhodapkar MV, Hussein MA, Rasmussen E, et al.: Clinical efficacy of high dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup trial Southwest Oncology Group SWOG 9628. Blood 104: 3520-3526, 2004.

38. Comenzo RL, Wally J, Kica G, et al.: Clonal immunoglob-ulin light chain variable region germline gene use in AL amyloidosis: association with dominant amyloid-related organ involvement and survival after stem cell transplantation. Br J Haematol 106:744-751, 1999.

39. Gertz MA, Kyle RA, Greipp PR: Response rates and survival in primary systemic amyloidosis. Blood77:257-262, 1991.

40. Abraham RS, Katzmann JA, Clark RJ, Bradwell AR, Kyle RA, Gertz MA: Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis. Am J Clin Pathol 119:274-278, 2003.

41. Kyle RA, Gertz MA, Greipp PR, et al.: A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, pred-nisone, and colchicine. N Engl J Med 336:1202-1207, 1997.

42. Skinner M, Anderson J, Simms R, et al.: Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med100:290-298, 1996.

43. Gertz MA, Kyle RA: Acute leukemia and cytogenetic abnormalities complicating melphalan treatment of primary systemic amyloidosis. Arch Intern Med 150:629-633, 1990.

44. Dhodapkar MV, Jagannath S, Vesole D, et al.: Treatment of AL-amyloidosis with dexamethasone plus alpha interferon. Leuk Lymphoma 27:351-356, 1997.

45. Lachmann HJ, Gallimore R, Gillmore JD, et al.: Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 122: 78-84, 200S.

46. Gertz MA, Lacy MQ, Lust JA, Greipp PR, Witzig TE, Kyle RA: Phase II trial of high-dose dexamethasone for previously treated immunoglobulin light-chain amyloidosis. Am J Hematol 61:115-119, 1999.

47. Gertz MA, Lacy MQ, Lust JA, Greipp PR, Witzig TE, Kyle RA: Phase II trial of high-dose dexamethasone for untreated patients with primary systemic amyloidosis. Med Oncol 16:104-109, 1999.

48. Palladini G, Anesi E, Perfetti V, et al.: A modified highdose dexamethasone regimen for primary systemic (AL) amyloidosis. Br J Haematol 113:1044-1046, 2001.

49. Palladini G, Perfetti V, Obici L, et al.: The association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloi-dosis ineligible for stem cell transplantation. Blood 103:2936-2938, 2004.

50. Singhal S, Mehta J, Desikan R, et al.: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565-1571, 1999.

51. Richardson PG, Barlogie B, Berenson J, et al.: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609-2617, 2003.

52. Gertz MA, Lacy MQ, Dispenzieri A, et al.: Stem cell transplantation for the management of primary systemic amyloidosis. Am J Med 113:549-555, 2002.

53. Comenzo RL, Gertz MA: Autologous stem cell transplantation for primary systemic amyloidosis. Blood 99:4276-4282, 2002.

54. Moreau P, Leblond V, Bourquelot P, et al.: Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br J Haematol 101:766-769, 1998.

55. Gertz MA, Lacy MQ, Dispenzieri A: Therapy for immunoglobulin light chain amyloidosis: the new and the old. Blood Rev 18:17-37, 2004.

56. Dispenzieri A, Lacy MQ, Kyle RA, et al.: Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol 19:3350-3356, 2001.

57. Dispenzieri A, Kyle RA, Lacy MQ, et al.: Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplant : a case control study. Blood 103: 3960-3963, 2004.

58. Dispenzieri A, Lacy MQ, Rajkumar SV, et al.: Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis. Amyloid 10: 257-261, 2003.

59. Gertz MA, Lacy MQ, Dispenzieri A, et al.: A multicenter phase II trial of 4'-iodo-4'deoxydoxorubicin (IDOX) in primary amyloidosis (AL). Amyloid 9:24-30, 2002.

60. Hrncic R, Wall J, Wolfenbarger DA, et al.: Antibody-mediated resolution of light chain-associated amyloid deposits. Am J Pathol 157:1239-1246, 2000.

61. Pepys MB, Herbert J, Hutchinson WL, et al.: Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 417:254-259, 2002.

This page intentionally left blank

0 0

Post a comment